AVEO Oncology Announces Participation at the 2021 SVB Leerink Global Healthcare Conference
February 18 2021 - 7:00AM
Business Wire
AVEO Oncology (Nasdaq: AVEO) today announced that Michael
Bailey, president and chief executive officer of AVEO, will
participate in a fireside chat at the 2021 SVB Leerink Global
Healthcare Conference on Thursday, February 25, 2021 at 3:00 p.m.
Eastern Time.
A live webcast of the fireside chat can be accessed by visiting
the investors section of the Company’s website at
www.aveooncology.com. A replay of the webcast will be archived for
30 days following the presentation date.
About AVEO Pharmaceuticals, Inc.
AVEO is an oncology-focused biopharmaceutical company committed
to delivering medicines that provide a better life for cancer
patients. AVEO’s strategy is to focus its resources toward
development and commercialization of its product candidates in
North America, while leveraging partnerships to support development
and commercialization in other geographies. AVEO’s lead candidate,
tivozanib, is approved as FOTIVDA® in the European Union and other
countries in the EUSA territory for the treatment of adult patients
with advanced RCC. Tivozanib is being studied in the TIVO-3 trial,
which is supporting a regulatory submission of tivozanib in the
U.S. seeking marketing approval as a treatment for relapsed or
refractory RCC. AVEO has previously reported promising early
clinical data on ficlatuzumab (anti-HGF mAb) in head and neck
cancer, acute myeloid leukemia and pancreatic cancer and is
conducting a randomized Phase 2 confirmatory clinical trial of
ficlatuzumab in head and neck cancer. AVEO’s earlier-stage pipeline
includes several monoclonal antibodies in oncology development,
including AV-203 (anti-ErbB3 mAb), AV-380 (anti-GDF15 mAb) and
AV-353 (anti-Notch 3 mAb). AVEO is committed to creating an
environment of diversity and inclusion as a foundation for
innovation.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO
within the meaning of the Private Securities Litigation Reform Act
of 1995 that involve substantial risks and uncertainties. All
statements, other than statements of historical fact, contained in
this press release are forward-looking statements. Actual results
or events could differ materially due to a number of important
factors, including risks discussed in the section titled “Risk
Factors” in AVEO’s most recent Annual Report on Form 10-K, its
quarterly reports on Form 10-Q and its other filings with the SEC.
The forward-looking statements in this press release represent
AVEO’s views as of the date of this press release. AVEO anticipates
that subsequent events and developments may cause its views to
change. While AVEO may elect to update these forward-looking
statements at some point in the future, it specifically disclaims
any obligation to do so. You should, therefore, not rely on these
forward-looking statements as representing AVEO’s views as of any
date other than the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210218005290/en/
AVEO: David Pitts, Argot Partners (212) 600-1902
aveo@argotpartners.com
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From May 2024 to Jun 2024
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Jun 2023 to Jun 2024